Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
369.84
-1.53 (-0.41%)
At close: Aug 15, 2025, 4:00 PM
345.50
-24.34 (-6.58%)
After-hours: Aug 15, 2025, 7:59 PM EDT
Madrigal Pharmaceuticals Revenue
Madrigal Pharmaceuticals had revenue of $212.80M in the quarter ending June 30, 2025, with 1,353.76% growth. This brings the company's revenue in the last twelve months to $515.55M, up 3,421.98% year-over-year. In the year 2024, Madrigal Pharmaceuticals had annual revenue of $180.13M.
Revenue (ttm)
$515.55M
Revenue Growth
+3,421.98%
P/S Ratio
15.78
Revenue / Employee
$976,415
Employees
528
Market Cap
8.24B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 180.13M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MDGL News
- 10 hours ago - Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further - Seeking Alpha
- 4 days ago - Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 8 days ago - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 15 days ago - Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term - Seeking Alpha
- 16 days ago - Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited - GlobeNewsWire
- 21 days ago - Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 - GlobeNewsWire